Moberg Pharma Partners with Karo Healthcare for European Launch of MOB-015/Terclara Moberg Pharma and Karo Healthcare have signed an exclusive agreement for the launch of MOB-015/Terclara in Europe, tapping into 19 markets.

Moberg Pharma Partners with Karo Healthcare for European Launch of MOB-015/Terclara #Sweden #Stockholm #Moberg_Pharma #Terclara #Karo_Healthcare

Moberg Pharma and Karo Healthcare Forge Exclusive Licensing Deal for Terclara Across Europe Moberg Pharma has secured an exclusive license with Karo Healthcare to commercialize MOB-015, Terclara in 19 major European markets. This collaboration enhances growth opportunities on a large scale.

Moberg Pharma and Karo Healthcare Forge Exclusive Licensing Deal for Terclara Across Europe #Sweden #Stockholm #Moberg_Pharma #Terclara #Karo_Healthcare

Karo Healthcare's Strategic Exclusive Licensing Deal With Moberg Pharma for MOB-015 in Europe Karo Healthcare has secured an exclusive licensing agreement with Moberg Pharma for the commercialization of MOB-015 across 19 European countries, enhancing its market presence with a new antifungal treatment.

Karo Healthcare's Strategic Exclusive Licensing Deal With Moberg Pharma for MOB-015 in Europe #Sweden #Stockholm #Moberg_Pharma #MOB-015 #Karo_Healthcare

Moberg Pharma's Terclara Launch in Norway: A New Era for Nail Fungus Treatment Moberg Pharma AB and Allderma have commenced the launch of Terclara® (MOB-015) in Norway, aiming to replicate its Swedish success in the treatment of nail fungus.

Moberg Pharma's Terclara Launch in Norway: A New Era for Nail Fungus Treatment #Norway #Oslo #Moberg_Pharma #Terclara #Allderma

Moberg Pharma's Phase 3 Study in North America Ends Without Primary Endpoint Success Moberg Pharma's Phase 3 study for MOB-015 in North America has not met its primary endpoint, leading the company to refocus efforts in the EU market.

Moberg Pharma's Phase 3 Study in North America Ends Without Primary Endpoint Success #Sweden #Stockholm #Moberg_Pharma #MOB-015 #Terclara